Deputy Physician-in-Chief for Breast Cancer Programs Larry Norton was interviewed on PBS NewsHour about a recent recommendation from a National Cancer Institute working group that proposed changing the definition of cancer.
In this “Ask the Expert” feature, Cara Anselmo, a registered dietitian nutritionist, discusses the importance of maintaining a healthy diet while undergoing breast cancer treatment.
A Memorial Sloan-Kettering study suggests that lymphedema of the arm, a swelling that can occur following breast cancer treatment, may be reduced by acupuncture.
Charles Sawyers, Larry Norton, and Kenneth Offit are being honored with special awards at the annual meeting of the world’s leading professional organization for cancer physicians and researchers.
Memorial Sloan-Kettering Clinical Genetics Service Chief Kenneth Offit discusses ways for women to clearly assess their risk for breast and ovarian cancer.
A New York State law that went into effect this month requires radiologists to inform women if they have dense breasts. Dr. Lee answers questions about the concept of breast density and what women should know.
Dr. Sclafani, who practices at Memorial Sloan-Kettering Commack, wants newly diagnosed patients to leave her office with hope and with a plan of action for treating the cancer.
New, potentially practice-changing research sheds light on the long-term benefits of estrogen-blocking tamoxifen therapy in women with early-stage breast cancer whose disease is estrogen-receptor positive.
A new Memorial Sloan-Kettering study has identified one of the proteins fueling the spread of some breast cancers, and researchers hope their findings will lead to the development of new diagnostic tools and drugs.
Dr. King talks about her research investigating why certain women develop breast cancer and about the long-term relationships she maintains with her patients.
Dr. Mehrara talks about the expertise of Memorial Sloan-Kettering plastic surgeons and how patients with breast cancer and head and neck cancer benefit from recent advances in reconstructive surgery.
A team of investigators from Memorial Sloan-Kettering has shown for the first time that tumor growth, metastasis, and chemotherapy resistance are connected to the same molecular changes inside breast cancer cells.
Dr. Morrow, Chief of Memorial Sloan-Kettering’s Breast Surgical Service, discusses how our patients with breast cancer are cared for by a true team of experts in every aspect of treatment and recovery.
A new study confirms that female childhood cancer survivors who were treated with radiation to the chest have a high risk of developing breast cancer at a young age – a risk that is comparable to that of women who have mutations in BRCA1 or BRCA2 genes.
Dr. Morrow is the first surgeon and the first person from Memorial Sloan-Kettering to receive the American Society of Clinical Oncology’s award, which recognizes breast cancer researchers who are also excellent mentors.
Memorial Sloan-Kettering is the first and only hospital in New York, New Jersey, and Connecticut to offer a new, more patient-friendly approach for doctors to precisely pinpoint and remove small breast cancers.
Breast Surgical Service Chief Monica Morrow provides perspective on assessing the quality of surgical breast cancer treatment in an editorial in the February 1 issue of the Journal of the American Medical Association.
Memorial Sloan-Kettering medical oncologist Clifford A. Hudis has been elected President of the American Society of Clinical Oncology, the world’s leading professional organization representing more than 30,000 physicians who care for people with cancer.
Research published in the November 19 issue of The Lancet finds that MRI use for breast cancer screening in women at high risk for the disease – due to family history or a genetic mutation – detects more cancers than screening mammography.
Memorial Sloan-Kettering Cancer Center researchers have identified a feature in the DNA of breast cancer cells that might indicate the likelihood a woman’s disease will become life threatening.
A multicenter study has found that for women who meet certain criteria — about 20 percent of all breast cancer patients — the surgery, called axillary node dissection, is unnecessary and does not improve survival or reduce rates of recurrence.
The new Evelyn H. Lauder Breast Center and the Memorial Sloan-Kettering Cancer Center Imaging Center opened in October offering patients advanced outpatient services for the diagnosis and treatment of breast cancer.
Medical oncologist Larry Norton commented on recommendations from a working group of the National Cancer Institute that suggested changing the definition of cancer.
Surgical oncologist Monica Morrow discussed a study she co-authored that found that more than three-quarters of women who opt for double mastectomies are not getting any benefit because their risk of cancer developing in the healthy breast is no greater than in women without cancer.
Diagnostic radiologist Carol Lee discussed a study that analyzed 30 years of data on breast cancer incidence and suggested that as many as a third of cancers detected through routine mammograms may not be life threatening. Epidemiologist Colin Begg also commented on the study in Reuters and Nature, and Memorial Sloan-Kettering’s Breast Disease Management Team authored a letter to the editor about the study that was published in the New York Times.
Watch medical oncologist Larry Norton speaking about the latest in breast cancer research on ABC's The View. Norton is Memorial Sloan-Kettering's Deputy Physician-in-Chief for Breast Cancer Programs as well as the Medical Director of the Evelyn H. Lauder Breast Center.
Memorial Sloan-Kettering Cancer Center physician-scientists report that women with small, node-negative, HER2-positive breast cancer may obtain a significant benefit from adjuvant chemotherapy with trastuzumab (Herceptin®), a drug previously shown to improve outcomes in advanced cancer and prevent the return of cancer in women diagnosed with higher-risk, early-stage, HER2-positive breast cancer. This study appears online in the journal Cancer, and will be published in a future print edition.
An international study led by researchers at Memorial Sloan-Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer.
The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. In an attempt to help physicians and patients weigh the risks and benefits of the available options, researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) are reporting in the Journal of Clinical Oncology on the development of a new prediction tool that calculates a patient’s individualized risk for recurrence five and ten years after surgery.
Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers at Memorial Sloan-Kettering Cancer Center shows that circulating tumor cells - cancer cells that break away from a primary tumor and disseminate to other areas of the body - can also return to and grow in their tumor of origin, a newly discovered process called “self-seeding.”
There is concern that mastectomy is over-utilized in the United States, which raises questions about the role of surgeons and patient preference in treatment selection for breast cancer. New data from an observational study published in the October 14 issue of the Journal of the American Medical Association, a theme issue on surgical care, found that breast-conserving surgery was presented and provided in the majority of patients evaluated.
The new Evelyn H. Lauder Breast Center of Memorial Sloan-Kettering Cancer Center and the Memorial Sloan-Kettering Cancer Center Imaging Center have opened, offering patients the most advanced outpatient services for cancer diagnosis and breast cancer treatment and detection.
New research led by investigators at Memorial Sloan-Kettering Cancer Center sheds light on a genetic function that gives breast cancer cells the ability to survive and spread to the bone years after treatment has been administered.
A study led by researchers at Memorial Sloan-Kettering Cancer Center has uncovered how breast tumors use a particular type of molecule to promote metastasis - the spread of cancer cells.
A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center found that breast cancer patients can be treated safely with a “dose-dense” regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.
ATLANTA, June 5, 2006 - A new multicenter study is the first to suggest that the prophylactic removal of the ovaries and fallopian tubes may provide a different benefit for women who carry a genetic mutation in the BRCA2 gene than for those who have a BRCA1 genetic mutation. The results of the study, which are being presented today at the annual American Society of Clinical Oncology meeting, also provide the strongest evidence to date that this surgery significantly reduces the overall risk of BRCA-associated breast and ovarian cancers.